Literature DB >> 8755637

IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations.

D G Efremov1, M Ivanovski, F D Batista, G Pozzato, O R Burrone.   

Abstract

The malignant B cells in chronic lymphocytic leukemia (CLL) typically express low-density membrane IgM or IgM/IgD. In vitro experiments have shown that the CLL cells can be induced to differentiate into cells that secrete immunoglobulin (Ig) and can occasionally undergo heavy (H) chain class switching. We now show that the CLL cells also undergo isotype-switching in vivo, since gamma and/or alpha H chain transcripts with identical FW3/CDR3/FW4 regions as the mu CLL transcripts were detected in all of the 13 investigated patients with IgM+ CLL. In most cases switching had occurred to alpha1 and gamma3, but CLL transcripts corresponding to the other gamma chain isotypes were also detected. In one case both the productively and nonproductively rearranged allele were found to undergo H chain class switching. CLL gamma transcripts were also present in surface IgG+ sorted B cells, demonstrating that a small subset of the CLL cells express membrane IgG. In addition, transcripts encoding secretary gamma2 and gamma3 H chains were detected in two cases, which suggests that some serum IgG could be produced by the leukemic clone. Analysis of sorted PBL showed that isotype-switching occurs in CLL cells that express the CD5 antigen. Finally, nucleotide sequence analysis showed that the mu, alpha, and gamma CLL transcripts are identical, demonstrating that the CLL cells do not accumulate somatic mutations in their variable region genes after the H chain class switching. These data provide in vivo evidence that isotype-switching is a frequent phenomenon in CLL, and indicate that a subset of the CLL lymphocytes progress to later stages of B cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755637      PMCID: PMC507430          DOI: 10.1172/JCI118792

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes.

Authors:  S M Fu; R J Winchester; T Feizi; P D Walzer; H G Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-11       Impact factor: 11.205

2.  Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia.

Authors:  D G Efremov; M Ivanovski; N Siljanovski; G Pozzato; L Cevreska; F Fais; N Chiorazzi; F D Batista; O R Burrone
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

3.  Clonal B-cell expansions in peripheral blood of HCV-infected patients.

Authors:  F Franzin; D G Efremov; G Pozzato; P Tulissi; F Batista; O R Burrone
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

4.  High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients.

Authors:  M J Deegan; J P Abraham; M Sawdyk; E J Van Slyck
Journal:  Blood       Date:  1984-12       Impact factor: 22.113

5.  Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B cell-associated surface antigens.

Authors:  J Gordon; H Mellstedt; P Aman; P Biberfeld; G Klein
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

6.  Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells.

Authors:  T H Tötterman; K Nilsson; C Sundström
Journal:  Nature       Date:  1980-11-13       Impact factor: 49.962

7.  Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM.

Authors:  G X Qian; S M Fu; D L Solanki; K R Rai
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

8.  IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing.

Authors:  M Wakai; S Hashimoto; M Omata; Z M Sthoeger; S L Allen; S M Lichtman; P Schulman; V P Vinciguerra; B Diamond; M Dono
Journal:  Autoimmunity       Date:  1994       Impact factor: 2.815

9.  Mitogen-induced switching of immunoglobulin heavy-chain class secretion in chronic B-lymphocytic leukaemia and immunocytoma cell populations.

Authors:  G Juliusson; K H Robèrt; L Hammarström; C I Smith; G Biberfeld; G Gahrton
Journal:  Scand J Immunol       Date:  1983-01       Impact factor: 3.487

10.  Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes.

Authors:  S M Fu; N Chiorazzi; H G Kunkel; J P Halper; S R Harris
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  11 in total

1.  Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis.

Authors:  E W Schettino; A Cerutti; N Chiorazzi; P Casali
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

2.  IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Authors:  Piers E M Patten; Charles C Chu; Emilia Albesiano; Rajendra N Damle; Xiao-Jie Yan; Dorothy Kim; Lu Zhang; Amanda R Magli; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Sergio Roa; Patricia K Mongini; Thomas MacCarthy; Matthew D Scharff; Nicholas Chiorazzi
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

3.  Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells.

Authors:  Andrea Cerutti; Hong Zan; Edmund C Kim; Shefali Shah; Elaine J Schattner; András Schaffer; Paolo Casali
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

4.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Authors:  F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

Review 5.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

6.  The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia.

Authors:  Chaohui Yuan; Charles C Chu; Xiao-Jie Yan; Davide Bagnara; Nicholas Chiorazzi; Thomas MacCarthy
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 7.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

8.  Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.

Authors:  M C Lanasa; S D Allgood; A D Volkheimer; J P Gockerman; J F Whitesides; B K Goodman; J O Moore; J B Weinberg; M C Levesque
Journal:  Leukemia       Date:  2009-10-15       Impact factor: 11.528

Review 9.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

10.  Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.

Authors:  Carmela Gurrieri; Peter McGuire; Hong Zan; Xiao-Jie Yan; Andrea Cerutti; Emilia Albesiano; Steven L Allen; Vincent Vinciguerra; Kanti R Rai; Manlio Ferrarini; Paolo Casali; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.